EGFR and dermatological toxicity: Patients with mCRC who received anti-EGFR monoclonal antibodies therapy reported experiencing skin toxicity of grade 3 to 4 (panitumumab 13% vs. cetuximab 10%), infusion reactions (panitumumab < 0.5% vs. cetuximab 2%), and hypomagnesaemia (panitumumab 7% vs. cetuximab 3%)21.